Vagus Nerve Stimulation (VNS) Research

This systematic review assessed the current evidence on vagus nerve stimulation (VNS) as a treatment for various gastrointestinal disorders. The authors evaluated both invasive and non-invasive VNS approaches across conditions including gastroparesis, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and postoperative ileus.

The review found that VNS can improve gastric motility and reduce inflammation through activation of the cholinergic anti-inflammatory pathway. Non-invasive transcutaneous auricular VNS (taVNS) showed particular promise for functional GI disorders, with several studies reporting improvements in symptoms such as nausea, bloating, and abdominal pain.

While the mechanistic rationale is strong, the vagus nerve being a major regulator of the gut-brain axis, the authors emphasize that most existing studies are small and heterogeneous. They call for larger, well-designed RCTs to establish optimal stimulation parameters and clarify which GI conditions benefit most from VNS therapy.

This systematic review evaluated the therapeutic potential of vagus nerve stimulation (VNS) across a range of autoimmune diseases. The authors examined both preclinical and clinical studies involving invasive VNS and non-invasive transcutaneous approaches in conditions such as rheumatoid arthritis, Crohn disease, systemic lupus erythematosus, and multiple sclerosis.

The evidence shows that VNS activates the cholinergic anti-inflammatory pathway, reducing pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and attenuating disease activity. Clinical trials in rheumatoid arthritis and Crohn disease have shown measurable reductions in disease severity scores and inflammatory biomarkers, with some patients achieving remission.

The review concludes that VNS represents a promising bioelectronic medicine approach for autoimmune conditions, particularly for patients who are refractory to conventional immunosuppressive therapies. However, the authors note that evidence remains limited by small sample sizes and short follow-up periods, and they call for larger multicenter trials to confirm long-term efficacy and safety.

This systematic review and meta-analysis evaluated the clinical efficacy of auricular vagus nerve stimulation (aVNS) for treating chronic and acute pain. The authors searched multiple databases and included randomized controlled trials comparing aVNS to sham stimulation.

The meta-analysis found statistically significant reductions in pain scores for both chronic pain conditions (such as migraine, fibromyalgia, and low back pain) and acute pain settings (including postoperative and procedural pain). Effect sizes were moderate to large, suggesting clinically meaningful benefits.

The review highlights aVNS as a promising non-pharmacological pain management approach, with a favorable safety profile and minimal side effects. The authors note that while results are encouraging, heterogeneity across studies and variability in stimulation parameters call for further standardized research to optimize treatment protocols.

This systematic review and meta-analysis evaluated the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for treating depressive disorder. The authors searched nine databases including PubMed, Embase, Cochrane Library, and several Chinese databases through November 2022, identifying 12 randomized controlled trials with 838 total participants.

The pooled analysis found that taVNS significantly improved depression scores and reduced Hamilton Depression Scale (HAMD) ratings compared to sham stimulation. Response rates for taVNS were higher than sham-taVNS and comparable to antidepressants alone. Notably, the combination of taVNS plus antidepressants showed similar efficacy to antidepressants alone but with fewer reported side effects, suggesting taVNS may serve as a useful adjunct therapy.

The overall quality of evidence was rated low to very low across subgroups, reflecting the relatively small number of studies and participants in each comparison. Nevertheless, the authors concluded that taVNS is an effective and safe method for alleviating depression, with a favorable side-effect profile compared to pharmacological treatment.

This large systematic review and meta-analysis evaluated the safety profile of transcutaneous auricular vagus nerve stimulation (taVNS) across 177 studies encompassing 6,322 subjects. The authors searched Medline, Embase, Web of Science, Cochrane, and Lilacs databases through April 2022 to comprehensively assess adverse event reporting and risk.

A notable finding was the poor state of safety reporting: 55% of studies did not mention the presence or absence of any adverse events at all, and only about 25% described at least one adverse event. Among studies that did report adverse events, the incidence rate was 12.84 per 100,000 person-minutes-days of stimulation. The most commonly reported effects were ear pain, headache, and tingling at the stimulation site - all mild and transient.

Critically, the meta-analysis found no statistically significant difference in the risk of developing an adverse event between active taVNS and sham/control conditions. No causal relationship was identified between taVNS and any severe adverse events. The authors concluded that taVNS is a safe and feasible option for clinical intervention, though they emphasized the need for improved adverse event reporting standards in future research.

This meta-analysis examined whether transcutaneous auricular vagus nerve stimulation (taVNS) can enhance cognitive performance in healthy individuals. The authors conducted a literature review and random-effects meta-analysis of 19 eligible studies, evaluating cognitive outcomes across multiple functional domains using both accuracy and response time measures.

The pooled analysis found a small but significant weighted effect size of g = 0.21 for overall cognitive performance, with executive function and accuracy-based measures showing the most meaningful improvements. Notably, stimulation parameters had a major influence on outcomes: tragus stimulation produced substantially larger effects (g = 2.39) compared to cymba concha stimulation (g = 0.48), a difference that was statistically significant in meta-regression analysis (Q = 39.84, p < .0001).

These findings suggest taVNS has genuine potential as a cognitive enhancement tool in healthy populations, particularly for executive function. However, the large variation in effect sizes depending on stimulation site highlights that protocol standardization is critical. The authors emphasized the need for continued research to identify optimal stimulation parameters before taVNS can be reliably recommended for cognitive enhancement.

This pilot study tested whether vagus nerve stimulation could treat Crohn's disease, an inflammatory bowel condition, by activating anti-inflammatory pathways.

Seven patients with moderate-to-severe Crohn's disease received VNS implants. After 6 months, 5 of 7 patients achieved clinical remission or response, with significant improvements in endoscopic inflammation and quality of life.

The study demonstrated that VNS could potentially offer a drug-free treatment option for inflammatory bowel disease, with the vagus nerve serving as a "natural brake" on gut inflammation.

This landmark study demonstrated that electrical stimulation of the vagus nerve could treat rheumatoid arthritis by activating the "inflammatory reflex" - a neural circuit that regulates immune responses.

Patients with treatment-resistant RA received implantable VNS devices. After stimulation, TNF and other inflammatory cytokines were significantly reduced, and disease activity improved substantially. Some patients who had failed multiple medications showed dramatic improvement.

This study provided proof-of-concept that bioelectronic medicine - using electrical signals to treat disease - could work in humans, opening a new frontier in treating inflammatory conditions.

This seminal Nature review describes the discovery and mechanisms of the inflammatory reflex - a neural circuit through which the vagus nerve regulates immune responses.

Vagal stimulation releases acetylcholine, which binds to receptors on immune cells and inhibits the release of pro-inflammatory cytokines like TNF, IL-1, and IL-6.